5 results
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids.
To obtain more information about the efficacy and tolerability of AD 923 in long-term management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids and receive therapy for BTP.
To determine the pharmacokinetic properties of a new elacridar formulation
Primary objective:Non-invasively determining the 11C-erlotinib brain uptake in DIPG patients by PET imaging.Secondary objective:Determining the EGFR expression in DIPG